Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments
Identifieur interne : 003A25 ( Istex/Curation ); précédent : 003A24; suivant : 003A26Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments
Auteurs : Jens Kovsted [Oman]Source :
- Development Policy Review [ 0950-6764 ] ; 2005-07.
Descripteurs français
- Wicri :
- topic : Droits de l'homme, Société, Santé publique.
English descriptors
- KwdEn :
- Absolute costs, Absolute prices, Active antiretroviral therapy, Active antiretroviral treatment, Aids activists, Aids exceptionalism, Aids treatment, Antiretroviral, Antiretroviral therapy, Antiretroviral treatment, Cape town, Central issue, Chronic disease, Country governments, Current level, Domestic governments, Economic pragmatists, Evidential base, Expensive treatment, First glance, Funding, Future rounds, Global, Global fund, Guideline, Haart, Haart drugs, Haart programmes, Haart treatment, Health emergency, Health sector, Health staff, Health workers, Heterosexual transmission, High level, Human immunodeficiency virus type, Human rights, Immune deficiency syndrome, Infrastructure, International agencies, International development, International organisations, International resources, Jens, Jens kovsted, Kovsted, Lancet, Large extent, Large reduction, Long latency period, Many countries, Media attention, Media interest, Nattrass, Oecd, Oecd countries, Organisation, Other hand, Other health interventions, Pharmaceutical companies, Pilot projects, Poor adherence, Poorer countries, Positive externalities, Programme, Public health, Public health sector, Real change, Regimen, Resistant strains, Risk behaviour, Scarce resources, Social science research, Success rate, Technical assistance, Total budget, Total costs, Treatment advocates, Treatment paradigm, Unaids, Unavoidable consequence, Unique opportunity, Viral load, Widespread testing, World bank, World health organisation, World health organization.
- Teeft :
- Absolute costs, Absolute prices, Active antiretroviral therapy, Active antiretroviral treatment, Aids activists, Aids exceptionalism, Aids treatment, Antiretroviral, Antiretroviral therapy, Antiretroviral treatment, Cape town, Central issue, Chronic disease, Country governments, Current level, Domestic governments, Economic pragmatists, Evidential base, Expensive treatment, First glance, Funding, Future rounds, Global, Global fund, Guideline, Haart, Haart drugs, Haart programmes, Haart treatment, Health emergency, Health sector, Health staff, Health workers, Heterosexual transmission, High level, Human immunodeficiency virus type, Human rights, Immune deficiency syndrome, Infrastructure, International agencies, International development, International organisations, International resources, Jens, Jens kovsted, Kovsted, Lancet, Large extent, Large reduction, Long latency period, Many countries, Media attention, Media interest, Nattrass, Oecd, Oecd countries, Organisation, Other hand, Other health interventions, Pharmaceutical companies, Pilot projects, Poor adherence, Poorer countries, Positive externalities, Programme, Public health, Public health sector, Real change, Regimen, Resistant strains, Risk behaviour, Scarce resources, Social science research, Success rate, Technical assistance, Total budget, Total costs, Treatment advocates, Treatment paradigm, Unaids, Unavoidable consequence, Unique opportunity, Viral load, Widespread testing, World bank, World health organisation, World health organization.
Abstract
Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.
Url:
DOI: 10.1111/j.1467-7679.2005.00297.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003A25
Links to Exploration step
ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<author><name sortKey="Kovsted, Jens" sort="Kovsted, Jens" uniqKey="Kovsted J" first="Jens" last="Kovsted">Jens Kovsted</name>
<affiliation wicri:level="1"><mods:affiliation>JKVS@novonordisk.com.</mods:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1111/j.1467-7679.2005.00297.x</idno>
<idno type="url">https://api.istex.fr/document/B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003A25</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003A25</idno>
<idno type="wicri:Area/Istex/Curation">003A25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments</title>
<author><name sortKey="Kovsted, Jens" sort="Kovsted, Jens" uniqKey="Kovsted J" first="Jens" last="Kovsted">Jens Kovsted</name>
<affiliation wicri:level="1"><mods:affiliation>JKVS@novonordisk.com.</mods:affiliation>
<country wicri:rule="url">Oman</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Development Policy Review</title>
<title level="j" type="alt">DEVELOPMENT POLICY REVIEW</title>
<idno type="ISSN">0950-6764</idno>
<idno type="eISSN">1467-7679</idno>
<imprint><biblScope unit="vol">23</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="465">465</biblScope>
<biblScope unit="page" to="482">482</biblScope>
<biblScope unit="page-count">18</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-07">2005-07</date>
</imprint>
<idno type="ISSN">0950-6764</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0950-6764</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absolute costs</term>
<term>Absolute prices</term>
<term>Active antiretroviral therapy</term>
<term>Active antiretroviral treatment</term>
<term>Aids activists</term>
<term>Aids exceptionalism</term>
<term>Aids treatment</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Cape town</term>
<term>Central issue</term>
<term>Chronic disease</term>
<term>Country governments</term>
<term>Current level</term>
<term>Domestic governments</term>
<term>Economic pragmatists</term>
<term>Evidential base</term>
<term>Expensive treatment</term>
<term>First glance</term>
<term>Funding</term>
<term>Future rounds</term>
<term>Global</term>
<term>Global fund</term>
<term>Guideline</term>
<term>Haart</term>
<term>Haart drugs</term>
<term>Haart programmes</term>
<term>Haart treatment</term>
<term>Health emergency</term>
<term>Health sector</term>
<term>Health staff</term>
<term>Health workers</term>
<term>Heterosexual transmission</term>
<term>High level</term>
<term>Human immunodeficiency virus type</term>
<term>Human rights</term>
<term>Immune deficiency syndrome</term>
<term>Infrastructure</term>
<term>International agencies</term>
<term>International development</term>
<term>International organisations</term>
<term>International resources</term>
<term>Jens</term>
<term>Jens kovsted</term>
<term>Kovsted</term>
<term>Lancet</term>
<term>Large extent</term>
<term>Large reduction</term>
<term>Long latency period</term>
<term>Many countries</term>
<term>Media attention</term>
<term>Media interest</term>
<term>Nattrass</term>
<term>Oecd</term>
<term>Oecd countries</term>
<term>Organisation</term>
<term>Other hand</term>
<term>Other health interventions</term>
<term>Pharmaceutical companies</term>
<term>Pilot projects</term>
<term>Poor adherence</term>
<term>Poorer countries</term>
<term>Positive externalities</term>
<term>Programme</term>
<term>Public health</term>
<term>Public health sector</term>
<term>Real change</term>
<term>Regimen</term>
<term>Resistant strains</term>
<term>Risk behaviour</term>
<term>Scarce resources</term>
<term>Social science research</term>
<term>Success rate</term>
<term>Technical assistance</term>
<term>Total budget</term>
<term>Total costs</term>
<term>Treatment advocates</term>
<term>Treatment paradigm</term>
<term>Unaids</term>
<term>Unavoidable consequence</term>
<term>Unique opportunity</term>
<term>Viral load</term>
<term>Widespread testing</term>
<term>World bank</term>
<term>World health organisation</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Absolute costs</term>
<term>Absolute prices</term>
<term>Active antiretroviral therapy</term>
<term>Active antiretroviral treatment</term>
<term>Aids activists</term>
<term>Aids exceptionalism</term>
<term>Aids treatment</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Cape town</term>
<term>Central issue</term>
<term>Chronic disease</term>
<term>Country governments</term>
<term>Current level</term>
<term>Domestic governments</term>
<term>Economic pragmatists</term>
<term>Evidential base</term>
<term>Expensive treatment</term>
<term>First glance</term>
<term>Funding</term>
<term>Future rounds</term>
<term>Global</term>
<term>Global fund</term>
<term>Guideline</term>
<term>Haart</term>
<term>Haart drugs</term>
<term>Haart programmes</term>
<term>Haart treatment</term>
<term>Health emergency</term>
<term>Health sector</term>
<term>Health staff</term>
<term>Health workers</term>
<term>Heterosexual transmission</term>
<term>High level</term>
<term>Human immunodeficiency virus type</term>
<term>Human rights</term>
<term>Immune deficiency syndrome</term>
<term>Infrastructure</term>
<term>International agencies</term>
<term>International development</term>
<term>International organisations</term>
<term>International resources</term>
<term>Jens</term>
<term>Jens kovsted</term>
<term>Kovsted</term>
<term>Lancet</term>
<term>Large extent</term>
<term>Large reduction</term>
<term>Long latency period</term>
<term>Many countries</term>
<term>Media attention</term>
<term>Media interest</term>
<term>Nattrass</term>
<term>Oecd</term>
<term>Oecd countries</term>
<term>Organisation</term>
<term>Other hand</term>
<term>Other health interventions</term>
<term>Pharmaceutical companies</term>
<term>Pilot projects</term>
<term>Poor adherence</term>
<term>Poorer countries</term>
<term>Positive externalities</term>
<term>Programme</term>
<term>Public health</term>
<term>Public health sector</term>
<term>Real change</term>
<term>Regimen</term>
<term>Resistant strains</term>
<term>Risk behaviour</term>
<term>Scarce resources</term>
<term>Social science research</term>
<term>Success rate</term>
<term>Technical assistance</term>
<term>Total budget</term>
<term>Total costs</term>
<term>Treatment advocates</term>
<term>Treatment paradigm</term>
<term>Unaids</term>
<term>Unavoidable consequence</term>
<term>Unique opportunity</term>
<term>Viral load</term>
<term>Widespread testing</term>
<term>World bank</term>
<term>World health organisation</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Droits de l'homme</term>
<term>Société</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Until recently, antiretroviral treatment against AIDS was perceived to be beyond the reach of the majority of patients in developing countries. This situation has changed drastically as international funding for AIDS treatment has swelled to several billion dollars a year. What has brought about this change? Analysis of the merit of six arguments often put forward against scaling up AIDS treatment in developing countries makes it clear that the most significant (and perhaps only) real change has been the large reduction in the price of the drugs. Although affordability is obviously a central issue, it is noticeable that most of the remaining arguments continue to be unresolved. This underlines the dangers of proceeding too fast towards treatment goals.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003A25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:B222C0C037167C7FAED8E8B4C7EA064BCD5EF02F |texte= Scaling Up AIDS Treatment in Developing Countries: A Review of Current and Future Arguments }}
This area was generated with Dilib version V0.6.32. |